• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PAR
Click for more information
1.69% 30.0¢

PARADIGM BIOPHARMACEUTICALS LIMITED.. - News & Media

Market Cap $103.1M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Paradigm Biopharmaceuticals Limited is a late-stage drug development company. The Company... Paradigm Biopharmaceuticals Limited is a late-stage drug development company. The Company is engaged in discovering, developing, and delivering pharmaceutical therapies. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS). Pentosan polysulfate sodium is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). It develops PPS under the brand name Zilosul. PPS also inhibits the synthesis of the metalloproteinase, MMP-3 (Troeberg) involved in degrading cartilage. PPS also include treatment of joint function, mobility, and pain in patients with MPS; treating alphavirus-induced arthralgia (such as Ross River virus and Chikungunya); chronic heart failure (HF) and acute respiratory distress syndrome (ARDS).More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Articles & Videos

Paradigm Biopharma on track to US Phase III osteo program

Paradigm Biopharma has announced its completion of a submission to the US FDA to progress to Phase III of its osteoarthritis 'program.'

19 Apr 2024 10:14 (AEST)

Paradigm Biopharma tests show reverse knee degradation in osteoarthritis patients

Paradigm Biopharma (ASX:PAR), which is investigating the use of iPPS in osteoarthritis, reported that patients have experienced knee cartilage regrowth.

18 Oct 2023 10:43 (AEDT)

Paradigm clocks 1-year trial result showing iPPS osteo pain decrease

Paradigm Biopharma (ASX:PAR) has reported that its year-long trial using iPPS resulted in OA patients reporting decreased pain.

10 Oct 2023 12:35 (AEDT)

Paradigm Biopharmaceuticals' (ASX:PAR) iPPS demonstrates multiple DMOAD signals in phase two study

Paradigm (ASX:PAR) has claimed a trial of its injectable pentosan polysulfate sodium (iPPS) drug showed the treatment may slow disease progression in knee osteoarthritis (OA).

04 Apr 2023 16:47 (AEST)



(20min delay)
Last
30.0¢ 		Change
0.005(1.69%) 		Mkt cap ! $103.1M
Open High Low Value Volume
30.0¢ 30.0¢ 29.5¢ $12.30K 41.06K

Buyers (Bids)

No. Vol. Price($)
6 74788 29.5¢
 

Sellers (Offers)

Price($) Vol. No.
30.0¢ 6862 4
View Market Depth
Last trade - 12.55pm 22/07/2024 (20 minute delay) ?
Last
29.8¢ 		  Change
0.005 ( 0.85 %)
Open High Low Volume
30.0¢ 30.0¢ 29.5¢ 5235
Last updated 13.27pm 22/07/2024 ?
PAR (ASX) Chart

Top Stories

Large fault structure and uranium anomalies picked up by Infini at Newfoundland play

Infini Resources Ltd has revealed the presence of a large fault structure connected to anomalies at its Portland Creek uranium project.
HBF to throw 10% vote behind NDC BidCo's buyout of Pacific Smiles Group Pacific Smiles Group has confirmed 10% shareholder HBF – the private health insurer – will vote in favour of PSQ's buyout by NDC BidCo.
High-grade copper results provide some relief to 29Metals after earlier mine shutdown 29Metals Ltd has reported positive results from a 3-hole program of drilling in Queensland, finding up to 4.8% copper.
Althea Group inks 'JV agreements' to boost marketing of cannabis-based beverage product in US market Althea Group (ASX:AGH) has inked agreements "to establish [a] joint venture" with Flora Growth Corporation to make cannabis-based beverages.
Pure Hydrogen inks MOU for 5 hydrogen buses in Saigon – days after Twiggy's FFI reeled back in Pure Hydrogen has confirmed it's executed an MOU with a Vietnam-based entity to develop hydrogen-fuelled buses.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.